Fighting Congenital Cytomegalovirus in Uterine Transplant Patients

Uterine transplantation is a game-changer for women with uterine factor infertility. It gives them a chance to carry their own pregnancy. But there's a catch - cytomegalovirus infection can be a major issue for transplant patients, especially during pregnancy. This infection can cause serious problems for both the mother and the baby.

Doctors are still figuring out how to manage cytomegalovirus in uterine transplant patients. They need to balance the risks of infection with the risks of treatment. One thing is clear: patients who are cytomegalovirus negative and receive an organ from a cytomegalovirus positive donor are at the highest risk of infection. These patients need close monitoring and possibly prophylaxis to prevent infection.

When it comes to pregnancy, the stakes are high. Cytomegalovirus infection can cause birth defects and developmental delays. That's why doctors need to be proactive in preventing and treating infection during pregnancy. They may use antiviral medications or cytomegalovirus-hyperimmune globulin to prevent or treat infection. The goal is to keep the mother and baby safe and healthy.

To make progress in this area, doctors need to share their experiences and data. A worldwide registry of cytomegalovirus infection in pregnancy could help them identify best practices and develop new treatments. By working together, they can reduce the risk of congenital cytomegalovirus infection and give uterine transplant patients a better chance of a healthy pregnancy.

The current approach is to give patients six months of prophylaxis after transplant. Doctors also check the patient's cytomegalovirus DNA viral load before embryo transfer. If the patient is at high risk of infection, they may receive prophylaxis around the time of embryo transfer. Frequent monitoring is crucial during pregnancy to catch any infection early. Treatment options depend on the severity of the infection and the stage of pregnancy.

In terms of treatment, doctors prefer to use valaciclovir or cytomegalovirus-hyperimmune globulin before 20 weeks' gestation. This is because valganciclovir can be teratogenic. However, in severe cases, valganciclovir may be necessary after 20 weeks. The key is to tailor treatment to each patient's needs and circumstances.

Uterine transplant patients are a unique group, but they can provide valuable insights into managing cytomegalovirus infection in pregnancy. By studying their experiences and developing effective treatment strategies, doctors can improve outcomes for all transplant patients.